This is a preprint.
The metacognitive paradox of OCD: confidence is globally reduced but shows increased sensitivity to local evidence
- PMID: 41001530
- PMCID: PMC12458574
- DOI: 10.21203/rs.3.rs-7609740/v1
The metacognitive paradox of OCD: confidence is globally reduced but shows increased sensitivity to local evidence
Abstract
Confidence is a critical metacognitive signal that guides performance. Biases in confidence, such as excessive doubt, are hallmark features of mental health disorders, especially obsessive-compulsive disorder (OCD). Yet, the underlying neurocognitive mechanisms and how they link to learning and decision-making remain elusive. We asked patients with OCD and matched healthy controls to perform a novel rule-shifting task incorporating trial-by-trial confidence ratings. Using a Bayes-optimal model, we identified two distinct confidence biases: while patients with OCD indicated lower overall confidence, their trial-by-trial confidence ratings more accurately tracked task-relevant information, rendering their confidence reports more Bayes-optimal than those of controls. These findings challenge the idea of a simple, unified metacognitive impairment in OCD. Instead, they suggest that OCD is linked to an enhanced responsiveness to environmental evidence and feedback during decision-making.
Keywords: Cognitive Flexibility; Confidence; Decision Making; Learning; Metacognition; Obsessive-Compulsive Disorder; Rule-Shifting.
Conflict of interest statement
Conflict of Interest Statement All authors declare no conflicts of interest. TUH consults for limbic ltd and holds shares in the company, which is unrelated to the current project. In the past three years, CP has consulted for Biohaven Pharmaceuticals, Ceruvia Neurosciences, UCB BioPharma, Freedom Biosciences, Transcend Therapeutics, Alco Therapeutics, Lucid/Care, Nobilis Therapeutics, Mind Therapeutics, F-Prime Capital, and Madison Avenue Partners. He holds equity in Alco Therapeutics, Mind Therapeutics, and Lucid/Care. He receives or has received research support from Biohaven Pharmaceuticals, Freedom Biosciences, and Transcend Therapeutics. He receives royalties from Oxford University Press and UpToDate. He has filed patents on pharmacological treatments for OCD and related disorders, psychedelic therapeutics, and autoantibodies in OCD. None of these relationships are of relevance to the work described here. For the past three years, BZ has consulted with Biohaven Pharmaceuticals and received royalties from Oxford University Press.
Figures
References
-
- Fleming S. M. & Lau H. C. How to measure metacognition. Front. Hum. Neurosci. 8, (2014).
-
- Desender K., Boldt A. & Yeung N. Subjective Confidence Predicts Information Seeking in Decision Making. Psychol. Sci. 29, 761–778 (2018). - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
